Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

New Gene Linked to Key Heart Attack Risk Factor

By Labmedica International staff writers
Posted on 26 Mar 2014
Image: Illumina HiSeq 2500 ultra-high-throughput sequencing system (Photo courtesy of Konrad Förstner).
Image: Illumina HiSeq 2500 ultra-high-throughput sequencing system (Photo courtesy of Konrad Förstner).
A previously unrecognized gene variation that makes humans have healthier blood lipid levels and reduced risk of heart attacks has been found.

The region of DNA where it was located had been implicated as being important in controlling blood lipid levels, but although this DNA region had many genes, none of them had any obvious link to blood lipid levels.

A team of scientists from the University of Michigan (Ann Arbor, Michigan, USA) and the Norwegian University of Science and Technology (Levanger, Norway) scanned the genetic information available from a biobank of a large number of Norwegians, focusing on variations in genes that change the way proteins function. Most of what they found turned out to be already known to affect cholesterol levels and other blood lipids. Total cholesterol (TC), high density lipid (HDL) cholesterol and triglycerides were measured by an enzymatic colorimetric method using the 911 Auto-Analyzer (Hitachi; Tokyo, Japan).

Genotyping of 5,771 individuals was performed using the Human Exome BeadChips (Illumina; San Diego, CA, USA) using their Infinium HD ultra protocol. The exome array includes 247,870 markers focused on protein-altering variants. Low-pass whole-genome sequencing was performed with exome enrichment on 76 cases with myocardial infarction (MI) and 76 controls using Illumina’s Hi-Seq 2500 ultra-high-throughput sequencing system. In a minority of the Norwegians who carried a particular change in a gene, blood lipid levels were much healthier and they had a lower rate of heart attack. This gene, known as Transmembrane 6 Superfamily Member 2 (TM6SF2), may also be involved in regulating lipid levels in the liver.

Cristen Willer, PhD, the senior author of the paper, said, “Cardiovascular disease presents such a huge impact on people's lives that we should leave no stone unturned in the search for the genes that cause heart attack. While genetic studies that focused on common variations may explain as much as 30% of the genetic component of lipid disorders, we still don't know where the rest of the genetic risk comes from. This approach of focusing on protein-changing variation may help us zero in on new genes faster.” The study was published on March 16, 2014, in the journal Nature Genetics.

Related Links:

University of Michigan
Norwegian University of Science and Technology
Illumina



PURITAN MEDICAL
EUROIMMUN AG
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.